Albuterol in the treatment of acute respiratory distress syndrome: A meta-analysis of randomized controlled trials / 世界急诊医学杂志(英文)
World Journal of Emergency Medicine
; (4): 165-171, 2015.
Article
em En
| WPRIM
| ID: wpr-789714
Biblioteca responsável:
WPRO
ABSTRACT
@#BACKGROUND: This meta-analysis of randomized controlled trials aimed to systematically evaluate the value of albuterol in the treatment of patients with acute respiratory distress syndrome (ARDS). DATA SOURCES: Randomized controlled trials on albuterol treatment of ARDS from its inception to October 2014 were searched systematically. The databases searched included: PubMed, Ovid EMBASE, Ovid Cochrane, CNKI, WANFANG and VIP. The trials were screened according to the pre-designed inclusion and exclusion criteria. We performed a systematic review and meta-analysis of the randomized controlled trials (RCTs) on albuterol treatment, attempting to improve outcomes, i.e. lowering the 28-day mortality and ventilator-free days. RESULTS: Three RCTs involving 646 patients met the inclusion criteria. There was no significant decrease in the 28-day mortality (risk difference=0.09;P=0.07,P for heterogeneity=0.22, I2=33%). The ventilator-free days and organ failure-free days were significantly lower in the patients who received albuterol (mean difference=-2.20;P<0.001,P for heterogeneity=0.49,I2=0% and mean difference=-1.71,P<0.001,P for heterogeneity=0.60,I2=0%). CONCLUSIONS: Current evidences indicate that treatment with albuterol in the early course of ARDS was not effective in increasing the survival, but significantly decreasing the ventilator-free days and organ failure-free days. Owing to the limited number of included trails, strong recommendations cannot be made.
Texto completo:
1
Índice:
WPRIM
Tipo de estudo:
Clinical_trials
/
Guideline
/
Systematic_reviews
Idioma:
En
Revista:
World Journal of Emergency Medicine
Ano de publicação:
2015
Tipo de documento:
Article